Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
BMC Medicine|August 25, 2024
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trialWenjuan Tian, Yulan Ren, Jing Lu, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 29, 2015
Metabonomic study of the effects of different acupuncture directions on therapeutic efficacyLiang Ju, Yan Wen, Jia Yin, et al.
JAMA Oncology|June 30, 2022
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical TrialTiantian Wang, Jie Tang, Hongying Yang, et al.
Human Molecular Genetics|July 3, 2014
A genome-wide association study identifies susceptibility loci of silica-related pneumoconiosis in Han ChineseMinjie Chu, Xiaoming Ji, Weihong Chen, et al.
BMC Medicine|May 9, 2025
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 studyZhenyu Lin, Peng Zhang, Ming Cai, et al.
Nature Communications|November 10, 2022
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junctionZhaoqing Tang, Yan Wang, Dan Liu, et al.
Signal Transduction and Targeted Therapy|March 14, 2025
PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trialYakun Wang, Jialin Lu, Xiaoyi Chong, et al.
Journal for Immunotherapy of Cancer|November 2, 2021
Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancerZhenyu Lin, Ming Cai, Peng Zhang, et al.
The Lancet. Gastroenterology & Hepatology|January 9, 2022
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trialXiangrui Meng, Tao Wu, Yonggui Hong, et al.
JAMA Oncology|December 16, 2021
Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical TrialYansong Lin, Shukui Qin, Zhiyong Li, et al.
Pageof 7